TY - JOUR
T1 - Molecular mechanism for agonist-promoted α2A-adrenoceptor activation by norepinephrine and epinephrine
AU - Nyrönen, Tommi
AU - Pihlavisto, Marjo
AU - Peltonen, Juha M.
AU - Hoffrén, Anna Marja
AU - Varis, Minna
AU - Salminen, Tiina
AU - Wurster, Siegfried
AU - Marjamäki, Anne
AU - Kanerva, Liisa
AU - Katainen, Erja
AU - Laaksonen, Leif
AU - Savola, Juha Matti
AU - Scheinin, Mika
AU - Johnson, Mark S.
PY - 2001
Y1 - 2001
N2 - We present a mechanism for agonist-promoted α2A-adrenergic receptor (α2A-AR) activation based on structural, pharmacological, and theoretical evidence of the interactions between phenethylamine ligands and α2A-AR. In this study, we have: 1) isolated enantiomerically pure phenethylamines that differ both in their chirality about the β-carbon, and in the presence/absence of one or more hydroxyl groups: the β-OH and the catecholic meta- and para-OH groups; 2) used [3H]UK-14,304 [5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; agonist] and [3H]RX821002 [2-(2-methoxy-1,4-benzodioxan-2yl)-2-imidazoline; antagonist] competition binding assays to determine binding affinities of these ligands to the high- and low-affinity forms of α2A-AR; 3) tested the ability of the ligands to promote receptor activation by measuring agonist-induced stimulation of [35S]GTPγS binding in isolated cell membranes; and 4) used automated docking methods and our α2A-AR model to predict the binding modes of the ligands inside the α2A-AR binding site. The ligand molecules are sequentially missing different functional groups, and we have correlated the structural features of the ligands and ligand-receptor interactions with experimental ligand binding and receptor activation data. Based on the analysis, we show that structural rearrangements in transmembrane helix (TM) 5 could take place upon binding and subsequent activation of α2A-AR by phenethylamine agonists. We suggest that the following residues are important in phenethylamine interactions with α2A-AR: Asp113 (D3.32), Val114 (V3.33), and Thr118 (T3.37) in TM3; Ser200 (S5.42), Cys201 (C5.43), and Ser204 (S5.46) in TM5; Phe391 (F6.52) and Tyr394 (Y6.55) in TM6; and Phe411 (F7.38) and Phe412 (F7.39) in TM7.
AB - We present a mechanism for agonist-promoted α2A-adrenergic receptor (α2A-AR) activation based on structural, pharmacological, and theoretical evidence of the interactions between phenethylamine ligands and α2A-AR. In this study, we have: 1) isolated enantiomerically pure phenethylamines that differ both in their chirality about the β-carbon, and in the presence/absence of one or more hydroxyl groups: the β-OH and the catecholic meta- and para-OH groups; 2) used [3H]UK-14,304 [5-bromo-N-(4,5-dihydro-1H-imidazol-2-yl)-6-quinoxalinamine; agonist] and [3H]RX821002 [2-(2-methoxy-1,4-benzodioxan-2yl)-2-imidazoline; antagonist] competition binding assays to determine binding affinities of these ligands to the high- and low-affinity forms of α2A-AR; 3) tested the ability of the ligands to promote receptor activation by measuring agonist-induced stimulation of [35S]GTPγS binding in isolated cell membranes; and 4) used automated docking methods and our α2A-AR model to predict the binding modes of the ligands inside the α2A-AR binding site. The ligand molecules are sequentially missing different functional groups, and we have correlated the structural features of the ligands and ligand-receptor interactions with experimental ligand binding and receptor activation data. Based on the analysis, we show that structural rearrangements in transmembrane helix (TM) 5 could take place upon binding and subsequent activation of α2A-AR by phenethylamine agonists. We suggest that the following residues are important in phenethylamine interactions with α2A-AR: Asp113 (D3.32), Val114 (V3.33), and Thr118 (T3.37) in TM3; Ser200 (S5.42), Cys201 (C5.43), and Ser204 (S5.46) in TM5; Phe391 (F6.52) and Tyr394 (Y6.55) in TM6; and Phe411 (F7.38) and Phe412 (F7.39) in TM7.
KW - receptor ligand
UR - http://www.scopus.com/inward/record.url?scp=0035032033&partnerID=8YFLogxK
U2 - 10.1124/mol.59.5.1343
DO - 10.1124/mol.59.5.1343
M3 - Article
C2 - 11306720
AN - SCOPUS:0035032033
SN - 0026-895X
VL - 59
SP - 1343
EP - 1354
JO - Molecular Pharmacology
JF - Molecular Pharmacology
IS - 5
ER -